Platelet Enzymatically Oxidized Phospholipids (eoxPL) Characterisation in a Healthy Cohort on and Off Aspirin

• Status: Completed
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Healthy volunteers (n = 28) were recruited from the workplace (14 male, 14 female; age range 20-50 years). Ethical approval, which included informed consent, was from Cardiff University, Schools of Medicine and Dentistry Research Ethics Committee (SMREC16/02). Following a 2-week period free from non-steroidal anti-inflammatory drugs (NSAIDs), peripheral blood was obtained and platelets isolated. Participants were commenced on aspirin 75 mg once daily for seven days and then provided a repeat blood sample. Following a 2-month period, participants were invited to repeat samples pre- and post-aspirin, and again a third time 2 months later.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Cardiff University
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• two-week washout period from any non-steroidal anti-inflammatory drugs (NSAIDs) use.

• Ability to take aspirin 75 mg once daily for seven days and sampled thereafter, before stopping the aspirin.

• Willingness to repeat this process after two months and four months of the initial sampling date.

Exclusion Criteria:

• Recent NSAID use